JP2022553839A5 - - Google Patents

Info

Publication number
JP2022553839A5
JP2022553839A5 JP2022525948A JP2022525948A JP2022553839A5 JP 2022553839 A5 JP2022553839 A5 JP 2022553839A5 JP 2022525948 A JP2022525948 A JP 2022525948A JP 2022525948 A JP2022525948 A JP 2022525948A JP 2022553839 A5 JP2022553839 A5 JP 2022553839A5
Authority
JP
Japan
Prior art keywords
here
antibody
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022525948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553839A (ja
JP7716399B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/058373 external-priority patent/WO2021087368A2/en
Publication of JP2022553839A publication Critical patent/JP2022553839A/ja
Publication of JP2022553839A5 publication Critical patent/JP2022553839A5/ja
Application granted granted Critical
Publication of JP7716399B2 publication Critical patent/JP7716399B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525948A 2019-11-01 2020-10-30 抗-cd45抗体及びそのコンジュゲート Active JP7716399B2 (ja)

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
US201962929194P 2019-11-01 2019-11-01
US201962929288P 2019-11-01 2019-11-01
US201962929283P 2019-11-01 2019-11-01
US201962929347P 2019-11-01 2019-11-01
US201962929601P 2019-11-01 2019-11-01
US201962929207P 2019-11-01 2019-11-01
US201962929137P 2019-11-01 2019-11-01
US62/929,194 2019-11-01
US62/929,137 2019-11-01
US62/929,347 2019-11-01
US62/929,283 2019-11-01
US62/929,288 2019-11-01
US62/929,207 2019-11-01
US62/929,601 2019-11-01
US201962940742P 2019-11-26 2019-11-26
US62/940,742 2019-11-26
US202062978147P 2020-02-18 2020-02-18
US62/978,147 2020-02-18
US202063015348P 2020-04-24 2020-04-24
US63/015,348 2020-04-24
US202063046164P 2020-06-30 2020-06-30
US202063046046P 2020-06-30 2020-06-30
US63/046,164 2020-06-30
US63/046,046 2020-06-30
US202063084903P 2020-09-29 2020-09-29
US63/084,903 2020-09-29
PCT/US2020/058373 WO2021087368A2 (en) 2019-11-01 2020-10-30 Anti-cd45 antibodies and conjugates thereof

Publications (3)

Publication Number Publication Date
JP2022553839A JP2022553839A (ja) 2022-12-26
JP2022553839A5 true JP2022553839A5 (cg-RX-API-DMAC7.html) 2023-11-14
JP7716399B2 JP7716399B2 (ja) 2025-07-31

Family

ID=75715351

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525948A Active JP7716399B2 (ja) 2019-11-01 2020-10-30 抗-cd45抗体及びそのコンジュゲート

Country Status (12)

Country Link
US (2) US12570756B2 (cg-RX-API-DMAC7.html)
EP (1) EP4051711A4 (cg-RX-API-DMAC7.html)
JP (1) JP7716399B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220091567A (cg-RX-API-DMAC7.html)
CN (2) CN114846028B (cg-RX-API-DMAC7.html)
AU (1) AU2020376934A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022008371A2 (cg-RX-API-DMAC7.html)
CA (1) CA3156740A1 (cg-RX-API-DMAC7.html)
IL (1) IL292628A (cg-RX-API-DMAC7.html)
MX (1) MX2022005249A (cg-RX-API-DMAC7.html)
TW (1) TWI904109B (cg-RX-API-DMAC7.html)
WO (1) WO2021087368A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019374055B2 (en) * 2018-10-30 2026-06-11 Regeneron Pharmaceuticals, Inc. Methods for allogeneic hematopoietic stem cell transplantation
AU2019370367A1 (en) 2018-10-30 2021-06-17 Magenta Therapeutics, Inc. Anti-CD45 antibodies and conjugates thereof
AU2020376934A1 (en) 2019-11-01 2022-06-02 Regeneron Pharmaceuticals, Inc. Anti-CD45 antibodies and conjugates thereof
WO2023235772A2 (en) * 2022-05-31 2023-12-07 Fred Hutchinson Cancer Center Humanized anti-cd45 antibodies and uses thereof
WO2024064771A1 (en) * 2022-09-20 2024-03-28 Vor Biopharma Inc. Anti-cd45-ign antibody drug conjugates and uses thereof
EP4637928A1 (en) * 2022-12-23 2025-10-29 Cimeio Therapeutics AG Antibodies targeting cd45
WO2025064944A1 (en) * 2023-09-20 2025-03-27 Vor Biopharma Inc. Anti-cd45 antibody-drug conjugate pharmaceutical compositions
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN120554516B (zh) * 2025-07-30 2025-10-24 杭州华大生命科学研究院 抗cd45抗体及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112661B1 (en) * 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
AU2006315825A1 (en) * 2005-11-10 2007-05-24 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
CA2674382C (en) * 2007-01-03 2016-05-31 Morphotek, Inc. High affinity antibodies that neutralize staphylococcus enterotoxin b
UY30994A1 (es) * 2007-04-02 2008-11-28 Amgen Fremont Inc Anticuerpos anti-ige
US9243057B2 (en) * 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
CN107287660A (zh) * 2011-09-30 2017-10-24 中外制药株式会社 离子浓度依赖性结合分子文库
CN104178454B (zh) * 2013-05-24 2019-03-08 益善生物技术股份有限公司 一种循环肿瘤细胞的富集、分析方法
JP6815331B2 (ja) * 2015-04-21 2021-01-20 ジェネンテック, インコーポレイテッド 前立腺がんの分析のための組成物及び方法
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
RS65120B1 (sr) 2015-11-25 2024-02-29 Immunogen Inc Farmaceutske formulacije i postupci za njihovu upotrebu
CA3016901C (en) 2016-03-07 2023-06-13 Actinium Pharmaceuticals, Inc. Stabilized radiolabeled anti-cd45 immunoglobulin compositions
CN109641051A (zh) * 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
US20200306301A1 (en) * 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
CN109991410B (zh) * 2017-12-29 2022-07-05 上海白泽医学检验所有限公司 一种含抗cd45单抗的组合物及其使用方法
US20200376135A1 (en) 2018-10-23 2020-12-03 Magenta Therapeutics, Inc. Fc silenced antibody drug conjugates (adcs) and uses thereof
CN113330026A (zh) 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
AU2019370367A1 (en) * 2018-10-30 2021-06-17 Magenta Therapeutics, Inc. Anti-CD45 antibodies and conjugates thereof
AU2020376934A1 (en) 2019-11-01 2022-06-02 Regeneron Pharmaceuticals, Inc. Anti-CD45 antibodies and conjugates thereof
KR20220154676A (ko) * 2020-02-18 2022-11-22 마젠타 테라퓨틱스 인코포레이티드 동종 이식을 위한 조성물 및 방법

Similar Documents

Publication Publication Date Title
JP2025160215A5 (cg-RX-API-DMAC7.html)
JP2022512629A5 (cg-RX-API-DMAC7.html)
JP7650819B2 (ja) 抗-cd45抗体薬物コンジュゲート及びその使用
JP2021500391A5 (cg-RX-API-DMAC7.html)
JP2022530089A5 (cg-RX-API-DMAC7.html)
CN106414465B (zh) 带电荷链接体及其在共轭反应上的应用
AU2021225125B9 (en) Antibody drug conjugate loaded with binary toxins and its application
CN105849086B (zh) 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
JP2020504112A5 (cg-RX-API-DMAC7.html)
US10576161B2 (en) Compositions and methods for the depletion of CD137+ cells
ES2939836T3 (es) Conjugados de moléculas de unión celular con agentes citotóxicos
JP5314590B2 (ja) カンプトテシン結合部分
US10695433B2 (en) Pyrrolobenzodiazepine-antibody conjugates
JP2019522050A5 (cg-RX-API-DMAC7.html)
JP2024096703A (ja) Cd5+細胞の枯渇のための組成物および方法
RU2014116878A (ru) Цитотоксические пептиды и их конъюгаты антитело-лекарственное средство
JP2016505019A5 (cg-RX-API-DMAC7.html)
US20150283263A1 (en) Pyrrolobenzodiazepine-antibody conjugates
CN107683146A (zh) 位点特异性抗体‑药物缀合物
CN108601952B (zh) 雷公藤内酯的葡萄糖缀合物、类似物及其用途
JP2022530438A5 (cg-RX-API-DMAC7.html)
JP2022531141A5 (cg-RX-API-DMAC7.html)
US20220177577A1 (en) Anti-cd117 antibody drug conjugates and uses thereof
WO2019108860A4 (en) Compositions and methods for the depletion of cd2+ cells
US20220226493A1 (en) Anthracycline antibody-drug conjugates and uses thereof